<DOC>
	<DOCNO>NCT02237638</DOCNO>
	<brief_summary>The primary objective study investigate safety tolerability profile therapeutic vaccine hVEGF26-104/RFASE determine effective dose hVEGF26-104/RFASE require neutralize VEGF serum , define VEGF level 9,0 pg/mL .</brief_summary>
	<brief_title>Phase I Study VEGF Vaccination Metastatic Solid Tumors</brief_title>
	<detailed_description>Angiogenesis ( formation new blood vessel pre-existing blood vessel ) play important role growth spread tumor . Angiogenesis regulate balance activator inhibitor . One angiogenic activator vascular endothelial growth factor ( VEGF , also refer VEGF-A ) . Over past decade , several angiogenesis inhibitor discover implemented therapy cancer patient . Bevacizumab ( humanize monoclonal antibody inhibit VEGF-A ) show improve survival different tumor type first second line therapy give various chemotherapy combination . Furthermore , research show survival benefit continue VEGF suppression bevacizumab beyond first progression metastatic colorectal cancer . So although repeat use bevacizumab chronic therapy much desire , currently feasible substantial disadvantage bevacizumab therapy . First , since bevacizumab offer temporary VEGF neutralization , need frequent repeat administration . Secondly , bevacizumab intravenous therapy , require hospitalization administration . Third , bevacizumab high production cost . These specific drawback long term monoclonal antibody therapy could circumvent use therapeutic cancer vaccine target VEGF . A vaccine able induce sustain VEGF suppression administer via intramuscular ( IM ) injection . In addition , vaccine likely inhibit VEGF effectively compare bevacizumab , vaccine induces polyclonal antibody response , result high avidity binding . Furthermore , believe endogenous antibody well tumor penetrate capacity , compare exogenously administer antibody . The vaccine hVEGF26-104 truncate synthetic peptide mimic VEGF protein consist 79 amino acid ( residue 26-104 ) . The vaccine contain antigen directs body 's polyclonal antibody response towards active site endogenous VEGF molecule . After bind antibody endogenous VEGF hormone longer able bind receptor ( VEGFR1 VEGFR2 ) consequently longer exert pro-angiogenic effect . To enhance immune response , RFASE , belong adjuvant group sulpholipopolysaccharides , use adjuvant . Primary objective - To investigate safety tolerability profile hVEGF26-104/RFASE . - To determine effective dose hVEGF26-104/RFASE require neutralize VEGF serum , define VEGF level 9,0 pg/mL . Secondary objective - To determine anti-VEGF antibody titer , induce hVEGF26-104/RFASE administration . - To determine effective dose hVEGF26-104/RFASE require neutralize VEGF plasma platelet sample . - To assess effect VEGF neutralization functional Ba/F3-R2 cell proliferation assay . Exploratory objectives - To assess cellular anti-tumor immune response induce hVEGF26-104/RFASE administration . - To assess immunomodulatory effect upon hVEGF26-104/RFASE administration . - To make preliminary assessment hVEGF26-104/RFASE suppress angiogenesis within tumor . - To assess immune infiltration regulation endothelial cell adhesion molecule within tumor . This open label single center phase I study . A `` 3 + 3 `` dose escalation design use . The study investigate sequential cohort consist 3 patient enrol treated applicable dose level . The study medication consist 1.0 mL hVEGF26-104 ( escalate dose 62.5 , 125 , 250 500 µg/mL ) combine 1.0 mL RFASE ( fix dose 20 mg/mL ) . Eligible subject receive three IM injection hVEGF26-104/RFASE day 0 ( primer ) , 14 28 ( booster ) . To assess potential toxicity adjuvant RFASE , 3 patient enrol first cohort study ( 62.5 μg/mL ) receive single injection 1.0 mL RFASE ( fix dose 20 mg/mL ) single agent 14 day prior first immunization hVEGF26-104/RFASE . If none 3 patient experience dose limit toxicity ( DLT ) certain dose level , one proceed next dose level . If one patient experience DLT certain dose level , another 3 patient assign dose level . In high dose escalation cohort , least 6 patient enrol . If VEGF longer neutralize , sign progression either ; patient receive another booster hVEGF26-104/RFASE order achieve VEGF neutralization . This booster repeat progressive disease , death reason withdrawal study . Eligible subject receive three intramuscular injection hVEGF26-104/RFASE dose-escalation day 0 ( primer ) , 14 28 ( booster ) , follow observation period 6 week . Blood drawn give timepoints assess safety , immunogenicity angiogenesis parameter . At screening , tumor biopsy perform baseline assessment angiogenesis immune infiltration . In case VEGF neutralize 8 week first hVEGF26-104 administration , patient ask undergo another biopsy week 10 ass possible change angiogenesis immune infiltration tumor . If VEGF longer neutralize , sign progression either ; patient receive another booster hVEGF26-104/RFASE order achieve VEGF neutralization .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically confirm advanced , solid malignancy . Refractory amenable standard therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Please refer Appendix II information . Willing able give write informed consent Patient ≥ 18 year age time signature inform consent Adequate hematological function : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , Hemoglobin ≥ 6.0 mmol/L . Adequate hepatic function : serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) , ALT AST ≤ 2.5 x ULN ( ≤ 5 time ULN liver metastasis present ) . Adequate renal function : eGFR ≥ 50ml/min PTINR/PTT &lt; 1.5 x ULN , unless coumarin derivative use Activated partial thromboplastin time ( APTT ) &lt; 1.25 x ULN ( therapeutic anticoagulation therapy allow , treatment interrupt biopsy judge treat physician ) Female patient childbearing potential may enrol study , patient Has practice adequate contraception 30 day prior first hVEGF26104/RFASE administration . Negative pregnancy test Has agree continue adequate contraception long VEGF neutralize . Major surgery within 28 day initiation study treatment Any serious nonhealing wound , ulcer , bone fracture within 28 day prior initiation study treatment . Deep venous thrombosis ( DVT ) pulmonary embolus ( PE ) within 1 year prior initiation study treatment . Uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) The patient schedule receive another vaccination DLT period . A previous serious allergic reaction vaccine angioedema anaphylaxis . Treatment bevacizumab within 6 week prior initiation study treatment . Uncontrolled autoimmune disease Primary secondary immunodeficiency , include HIV Treatment glucocorticoid derivative equivalent dose ≥ 10mg prednisone day . Female patient : patient pregnant lactating . When patient schedule receive anticancer treatment . Chemotherapy within 28 day prior initiation study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>VEGF</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Angiogenesis</keyword>
</DOC>